Glaukos Corp Ebitda Over Time
| GKOS Stock | USD 143.65 0.96 0.67% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Glaukos Corp Performance and Glaukos Corp Correlation. Glaukos |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Glaukos Corp. If investors know Glaukos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Glaukos Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 18.963 | Earnings Share (2.93) | Revenue Per Share 7.056 | Quarterly Revenue Growth 0.239 | Return On Assets (0.08) |
The market value of Glaukos Corp is measured differently than its book value, which is the value of Glaukos that is recorded on the company's balance sheet. Investors also form their own opinion of Glaukos Corp's value that differs from its market value or its book value, called intrinsic value, which is Glaukos Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Glaukos Corp's market value can be influenced by many factors that don't directly affect Glaukos Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Glaukos Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Glaukos Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Glaukos Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare Glaukos Corp and related stocks such as Orthopediatrics Corp, CONMED, and LivaNova PLC Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KIDS | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (4.8 M) | (3.2 M) | (4 M) | (6.9 M) | (4.5 M) | (22.3 M) | (7.2 M) | (7.9 M) | (8.4 M) | (8.8 M) |
| CNMD | 1.7 M | 111.3 M | 111.8 M | 104.4 M | 98.5 M | 95.1 M | 90 M | 105.5 M | 133.1 M | 73.9 M | 113.6 M | 158.4 M | 7.8 M | 192.5 M | 202.1 M |
| LIVN | (5.7 M) | 61.3 M | 80 M | 92.9 M | 113.3 M | (30.7 M) | 243.8 M | 211.3 M | 156.2 M | 131 M | (225.9 M) | (6.3 M) | 30.9 M | 39 M | 28.9 M |
| FNA | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 12 M | (2.3 M) | (47.9 M) | (21.8 M) | (20.7 M) |
| OFIX | 20.9 M | 111.8 M | 111.2 M | 81.8 M | 50.6 M | 27.4 M | 39.4 M | 35.8 M | 36.2 M | 49.6 M | 32.7 M | 17.9 M | 12.6 M | (79.5 M) | (75.5 M) |
| BRKR | (161 K) | 158.6 M | 217.5 M | 238.1 M | 209.3 M | 228.6 M | 257.3 M | 298.3 M | 346.8 M | 383 M | 320.7 M | 497.1 M | 545.3 M | 599 M | 629 M |
| NVRO | (19.1 M) | (19.1 M) | (19.1 M) | (25.1 M) | (28.2 M) | (61.8 M) | (21.8 M) | (27.1 M) | (37.9 M) | (88.7 M) | (54.7 M) | (102.4 M) | 21 M | (78.3 M) | (74.4 M) |
| ITGR | 22.5 M | 61.7 M | 24.9 M | 60.8 M | 76.5 M | 14.5 M | 203.8 M | 232.6 M | 243.8 M | 236.1 M | 207.6 M | 215.3 M | 215.4 M | 256.5 M | 269.3 M |
| IRMD | 1.5 M | 1.5 M | 1.5 M | 2.9 M | 3.2 M | 11.7 M | 11.2 M | 2.6 M | 7.1 M | 9.9 M | 582.7 K | 11.2 M | 16.3 M | 20 M | 21 M |
| SRDX | 1.7 M | 19.3 M | 22.5 M | 22.2 M | 21.7 M | 28.6 M | 9.3 M | 10.8 M | 10.3 M | 967 K | 12.2 M | (12.2 M) | 15.2 M | 1.2 M | 1.1 M |
| SGHT | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (23.6 M) | (31.7 M) | (57.2 M) | (80.5 M) | (49.4 M) | (51.9 M) |
Glaukos Corp and related stocks such as Orthopediatrics Corp, CONMED, and LivaNova PLC Ebitda description
My Equities
My Current Equities and Potential Positions
| Glaukos Corp | GKOS |
| Classification | Medical Equipment |
| Location | California; U.S.A |
| Exchange | New York Stock Exchange |
USD 143.65
Additional Tools for Glaukos Stock Analysis
When running Glaukos Corp's price analysis, check to measure Glaukos Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaukos Corp is operating at the current time. Most of Glaukos Corp's value examination focuses on studying past and present price action to predict the probability of Glaukos Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Glaukos Corp's price. Additionally, you may evaluate how the addition of Glaukos Corp to your portfolios can decrease your overall portfolio volatility.